1.Recommendations for the diagnosis and treatment of rheumatic fever in China
Jieruo GU ; Zhiming LIN ; Youlian WANG ; Long LI ; Pingting YANG ; Yan ZHAO
Chinese Journal of Internal Medicine 2023;62(9):1052-1058
Rheumatic fever is an autoimmune disease characterized by recurring acute or chronic systemic connective tissue inflammation caused by group A streptococcal infection in the throat. Although rheumatic fever is common in China, there is a lack of standardized criteria for the diagnosis and treatment of this condition. Based on evidence and guidelines from China and other countries, the Chinese Rheumatology Association developed standardized criteria for the diagnosis and treatment of this disease in China. The aim was to standardize rheumatic fever diagnosis methods, treatment opportunities, and strategies for both short-and long-term treatment, so as to reduce irreversible damage and improve prognosis.
2.Practice guideline for patients with ankylosing spondylitis/spondyloarthritis
Ya XIE ; Kehu YANG ; Qing LYU ; Yi ZHENG ; Cibo HUANG ; Zhenbin LI ; Shengyun LIU ; Linkai FANG ; Xiaoqin WANG ; Yuqi ZHOU ; Biling LIANG ; Zhengang ZHA ; Bo JIANG ; Jie ZHOU ; Zhivko YANKOV ; Jieruo GU
Chinese Journal of Internal Medicine 2020;59(7):511-518
In recent years, the clinical experts consensuses or guidelines of ankylosing spondylitis (AS)/spondyloarthritis (SpA) have been constantly updated, but to better understand and practice, patient self-participation management is one of the key points to improve the level of diagnosis and treatment. Through questionnaire survey of these patients, we screened out the most concerned issues, and established the AS/SpA patient practice guideline working group with multidisciplinary physicians and patients. Fifteen opinions, as the AS/SpA patient practice guidelines, are proposed in accordance with the relevant principles of the "WHO guidelines development manual" , and with the international normative process.
3.Practice guidelines for patients with rheumatoid arthritis
Linkai FANG ; Caihong HUANG ; Ya XIE ; Qi LIU ; Xiaoqin WANG ; Dongyi HE ; Yi LIU ; Yuqi ZHOU ; Kun WANG ; Yujie LI ; Xuemei XIAN ; Shuangyan CAO ; Xiaofeng ZENG ; Kehu YANG ; Jieruo GU
Chinese Journal of Internal Medicine 2020;59(10):772-780
In recent years, the clinical guidelines for the diagnosis and treatment of rheumatoid arthritis (RA) have been constantly updated. Among the general principles, it is particularly emphasized that, in order to improve the ratio of treat to target(T2T) of RA, doctors and patients should work together to negotiate the details of the guidelines. Therefore, it is important for patients to further understand the disease and clinical guidelines of RA, and to better cooperate with doctors. This study was based on the most concerned issues of RA patients and international standard procedure of guideline study, we organized the working group and introduce the following 16 recommendations constituting the RA patients′ practice guidelines.
4.Practice guideline for patients with osteoporosis
Minli QIU ; Ya XIE ; Xiaohong WANG ; Xiaoqin WANG ; Dongbao ZHAO ; Huiqiong ZHOU ; Yuqi ZHOU ; Li YAN ; Biling LIANG ; Huanling SHEN ; Shuangyan CAO ; Yue DING ; Jieruo GU ; Xiaofeng ZENG ; Kehu YANG
Chinese Journal of Internal Medicine 2020;59(12):953-959
In recent years, osteoporosis (OP) has become one of the main diseases affecting the health of middle-aged and elderly people in China, and the prevalence of OP has increased significantly. The clinical diagnosis and treatment guidelines for this disease are also constantly updated. The overall principles speciallyemphasise that doctors and patients need to work together to negotiate the details of the diagnosis and treatment guidelines, in order to improve the OP clinical diagnosis and treatment rate. Therefore, patients′ knowledge of the disease, understanding of clinical guidelines, and cooperation with doctors to implement diagnosis and treatment plans are very important. In this study, from the most concerned issues of the patients, we established the OP patient practice guideline working group. 14 recommendations, as the OP patient practice guidelines, are proposed in accordance with the relevant principles of the "World Health Organization guidelines development manual" and the international normative process.
5.Nationwide multicentre clinical research on flurbiprofen cataplasm for treating patients with osteoarthritis pain
Hua YE ; Xiaoxia ZUO ; Jieruo GU ; Ping ZHU ; Hejian ZOU ; Xiangpei LI ; Shaoxian HU ; Zhiyi ZHANG ; Lingyun SUN ; Zhanguo LI
Chinese Journal of Rheumatology 2012;16(9):606-610
ObjectiveTo study the effect and safety of flurbiprofen cataplasm on osteoarthritis pain in Chinese patients.MethodsOne hundred and eighty-three patients were divided into flurbiprofen cataplasm group,indometacin cataplasm group and Qizheng-xiaotong plaster group randomly.The score of pain,stiffness and physical function were analyzed with WOMAC scale and adverse reactions were also assessed.KruskalWallis H test,Nemenyi test and CMH tese were used.ResultsAfter treatment,the VAS value of the three groups decreased significantly and the VAS difference value of the flurbiprofen cataplasm group changed the most significantly(the changes of VAS value in flat walking,up and down stairs,nighttime,rest and weightbearing were 31±21,35±20,24±19,20±18 and 37±20 respectively).Meanwhile,the value of stiffness and physical function decreased significantly.In terms of safety,flurbiprofen cataplasm group and the indome-tacin cataplasm group were better than Qizheng-xiaotong plaster group.But in sense of constriction,the flurbiprofen cataplasm group was better than the indometacin eataplasm group.ConclusionFlurbiprofen Cataplasm,with its favorable analgesic effect,is suitable for general clinical use.It can reduce stiffness,improvephysical function,and has good safety profile.
6.Summary of the 2008 national autoantibody testing quality control
Qiuxia LI ; Qiujing WEI ; Qiguang LI ; Jieruo GU
Chinese Journal of Rheumatology 2010;14(6):408-412
Objective To consecutively understand the national clinical testing status and to reassure the quality-control of autoantibody detection. Methods Letter or telephone notification were conducted to the participating hospitals or departments. Autoantibodies for quality control survey included anti-nuclear anti-body (ANA), anti-double-stranded DNA (anti-dsDNA), anti-extractable nuclear antigens (A-ENA), anti-mitochondria antibody (AMA)/anti-smooth muscle antibody (ASMA), and anti-citrulline antibody (anti-CCP). Each had 3 control samples, and altogether 15 samples for testing. Sample distribution and data analysis were double-blinded. Results One hundred and two hospitals/departments participated in the national quality-control survey. The accurate rate for this survey was 70%, 88%, 93%, 85%, 79% respectively for ANA, anti-dsDNA, AMA, ASMA and anti-CCP. Anti-ENAs were further divided into anti-RNP, Sm, SSA, SSB and Scl-70 subgroups, and the accurate rate was 88%, 77%, 92%, 93% and 87% respectively. Conclu-sion Compared to the previous 4 national surveys, the accurate rates of ANA, anti-dsDNA, anti-ENAs, AMA in our country's autoantibody testing is improved, and the detection rate of ASMA and anti-CCP antibody is also increased. More hospitals and testing items can test these autoantibodies, which implies that autoantibody testing status has been improving in our country.
7.The value of ankylosing spondylitis disease activity score in Chinese ankylosing spondylitis patients
Manlong XU ; Zhiming LING ; Zetao LIAO ; Jinxian HUANG ; Li LI ; Yanling WEI ; Qiujing WEI ; Qiuxia LI ; Yingying XIE ; Yanli ZHANG ; Tianwang LI ; Jieruo GU
Chinese Journal of Rheumatology 2010;14(3):177-181
Objective To validate the discriminatory capacity of the new ankylosing spondylitis disease activity scores (ASDAS) in Chinese ankylosing spondylitis (AS) patients, and assess its clinical value. Method One hundred and twenty-nine patients with AS was included in the study, in which 87 were par-ticipat clinical trials with Etanercept (n=87) and 42 were participants of clinical trails with. The disease activity and treatment effecticacy were assessed by ASDAS, BASDAI and patient global assessment. Discriminatory ability of all the measures was analyzed as standardized mean difference (SMD) and (-score. Pearson's correlation, two indepen -dent samples t test and simple linear regression model were used for statistical analysis. Result The four ASDAS scores correlated well with patient global assessment (r=0.56~0.74), ESR (r=0.50~0.80) and CRP (r=0.50~0.69) both at baseline and the changes form baseline to 6 weeks after treatment. The four ASDAS outperformed BASDAI, patient global assessment, ESR and CRP in differentiating patients with different levels of disease activity and patients with different levels of change. There was little difference in performance between the four ASDAS versions. Conclusion The four ASDAS are highly discriminatory in evaluating the disease activity and the efficacy of drugs in Chinese AS patients, showing a significant value in clinical practice.
8.Construction of tissue engineered cartilage in vivo with poly(lactide-co-glycolic acid) composited with collagen Ⅱ and growth factors
Gaoxin XIONG ; Zhengang ZHA ; Wencheng TAN ; Hao WU ; Jieruo LI ; Hongsheng LIN ; Jisheng XIA ; Xinpei HUANG ; Mei TU ; Jiaqing ZHANG
Chinese Journal of Tissue Engineering Research 2010;14(16):3028-3032
BACKGROUND: The development of cartilage tissue engineering provides novel ideas for treatment of articular cartilage defects and implements construction of tissue-engineered cartilage in vivo.OBJECTIVE: To investigate the feasibility of constructing tissue-engineered osteochondral composite through bone marrow stem cells(BMSCs) cultured on the poly(lactide-co-glycolic acid) (PLGA), which was modified with collagen and cellular growth factors.METHODS: PLGA was made by phase separation technique, composited with collagen Ⅱ, basic fibroblast growth factor, and transforming growth factor-β1. The BMSCs of passage 3 were cultured on the above scaffolds. Thirty-six SD rats were randomly divided into experimental, control, and blank groups. These three groups received implantation of BMSCs composited with growth factors and collagen-PLGA, implantation of BMSCs composited with collagen-PLGA, and implantation of collagen-PLGA into the muscle, respectively. At 4, 8, and 12 weeks after surgery, cell directional differentiation and growth were examined by gross observation, hematoxylin-eosin staining, toluidine blue staining, collagen Ⅱ staining, and scanning electron microscope.RESULTS AND CONCLUSION: Gross observation showed that there were many chondroid tissues in the experimental group and fibrous tissues in the control and black groups. Stainings and electron microscope revealed that many chondroblasts and a few osteoclasts appeared in the composite of the experimental group. Toluidine blue and collagen Ⅱ stainings were positive in the experimental group and negative in the control and blank groups. These findings demonstrate that PLGA modified with collagen had a good cellular compatibility. BMSCs cultured on PLGA, which was modified with collagen and cellular growth factors, can construct the tissue-angineered osteochondral composite in rats.
9.The effects of microenvironment on tissue-engineered osteochondral composite.
Jieruo LI ; Zhiyong SHU ; Zhengang ZHA
Journal of Biomedical Engineering 2009;26(2):433-436
It is currently reported that extracellular matrix, biological scaffolds, conditions of stress, nutrients and metabolic waste play very important roles in tissue-engineered osteochondral composite. In this paper, we have made a review of their effects on such composite.
Cartilage
;
chemistry
;
physiology
;
Chondrocytes
;
Connective Tissue
;
growth & development
;
Extracellular Matrix
;
chemistry
;
Humans
;
Stress, Mechanical
;
Tissue Engineering
;
methods
;
Tissue Scaffolds
;
chemistry
10.The expression of autophagy and related genes in patients with active systemic lupus erythematosus
Jijun ZHAO ; Meirong LI ; Caisheng LU ; Jieruo GU ; Yunfeng PAN ; Buyun YU
Chinese Journal of Rheumatology 2009;13(3):148-151
Objective To investigate the autophagy and the expression of its related genes in the peripheral blood mononuclear cells (PBMCs) of active systemic lupus erythematosus (SLE) patients.Methods Patients with newly onset or recently-diagnosed SLE (n=20) were enrolled.RA patients (n=10) and healthy blood donors (n=10) were used as controls.PBMCs from all subjects were immediately isolated by Ficoll-Hypaque density gradient centrifugation.And then monocytes were removed by wall sticking method.The morphology was observed using transmission electron microscopy (TEM).Messenger RNA (mRNA) expression of Beclin 1 and microtubule-associated protein 1-light chain 3 (MAPLC3) were determined by reverse transcription polymerase chain reaction (RT-PCR) and real-time quantitative RT-PCR respectively.Results TEM showed autophagic phenomenon in PBMCs from active SLE.On the mRNA level,expression of Beclin 1 and LC3 was significantly increased in fresh isolated SLE cells as compared with RA or healthy donor's PBMCs.Conclusion Based on these results,we can conclude that autophagy occurs in active SLE and the expression of its related genes is significantly higher in active SLE than in RA or normal controls.The enhanced autophagy may indicate its role in the pathogenesis of SLE.

Result Analysis
Print
Save
E-mail